Tradestie Institutional Equity Comparison Engine · Market Close May 08, 2026

AKRO vs KZR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KZR Captures Overall Composite Edge (60.1 BUY vs 60.0 BUY), While AKRO Leads 3–1 on Growth & Valuation Pillars

KZR Overall Winner 6-Pillar Tally: AKRO 3 – 1 KZR (2 Tie) Matrix Metrics: AKRO 3 – 1 KZR

As of May 08, 2026, Kezar Life Sciences, Inc. (KZR) captures the overall head-to-head institutional edge over Akero Therapeutics, Inc. (AKRO) on higher Unified Composite conviction (60.1/100 BUY vs. 60.0/100 BUY) after splitting the core matrix 1–3 (led by Options & Positioning), while AKRO wins 3–1 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus KZR at $7.29 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: KZR earns the overall head-to-head edge with a stronger Unified Composite Score (60.1/100 BUY vs. AKRO 60.0/100 BUY) and 0.60β · 8% Vol risk profile, whereas AKRO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKRO vs KZR
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91
KZR NASDAQ Head-to-Head Winner
Kezar Life Sciences, Inc. Common Stock
Pharmaceutical Preparations
$7.29
-0.95% 1D
Market Cap $54.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.60β · 8% Vol
Unified Composite Score
60.1 / 100 BUY
Tech 40.0 Fund 51.0 Flow 56.0 Mom 58.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 53
RSI-14: 52.6 · SMA20: $7.33 · SMA50: $7.12

6-Pillar Scorecard Institutional Category Breakdown (AKRO 3 – 1 KZR)

Columns: Metric · AKRO · KZR
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AKRO
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $4.5B $54.4M
3. Profitability & Quality AKRO
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -34.5% -59.9%
4. Balance Sheet & Cash Flow AKRO
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $11.95 Book/Sh · -34.5% ROE $9.56 Book/Sh · -59.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KZR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 7.3% (30th %ile) 37.2% (9th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Pharmaceutical Preparations Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKRO (3) vs KZR (1)
Institutional Metric AKRO KZR Criterion Row Edge
Market Capitalization
Scale
$4.5B $54.4M Larger Scale AKRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-34.5% -59.9% Higher ROE AKRO
52-Week Range Position
Momentum
90% ($21–$58) 94% ($4–$8) Stronger Trend KZR
Beta / 30D Volatility
Risk Regime
0.90β · 2% Vol 0.60β · 8% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 60.1 / 100 (BUY) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.95 Book/Sh · -34.5% ROE) N/A ($9.56 Book/Sh · -59.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KZR +2.43 pp
AKRO: +1.37% · KZR: +3.8%
3M Horizon KZR +33.74 pp
AKRO: +22.48% · KZR: +56.22%
6M Horizon KZR +41.23 pp
AKRO: -0.11% · KZR: +41.12%
1Y Horizon KZR +26.2 pp
AKRO: +27.72% · KZR: +53.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs KZR. Trailing 12-month operating profitability (AKRO 0.0% vs KZR 0.0%) and valuation multiples (AKRO N/M vs KZR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M
KZR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KZR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 37.2%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KZR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KZR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $54.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AKRO vs KZR Key Questions & Quantitative Answers

As of May 08, 2026, Kezar Life Sciences, Inc. (KZR) captures the overall head-to-head institutional edge over Akero Therapeutics, Inc. (AKRO) on higher Unified Composite conviction (60.1/100 BUY vs. 60.0/100 BUY) after splitting the core matrix 1–3 (led by Options & Positioning), while AKRO wins 3–1 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus KZR at $7.29 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: KZR earns the overall head-to-head edge with a stronger Unified Composite Score (60.1/100 BUY vs. AKRO 60.0/100 BUY) and 0.60β · 8% Vol risk profile, whereas AKRO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

AKRO leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with KZR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus N/A for KZR. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KZR.

AKRO and KZR trade at balanced relative valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas KZR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus KZR (-59.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, KZR carries 37.2% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.60β · 8% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 08, 2026. For educational research only; not investment advice.